BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

A-623: Phase IIb resumed

Anthera resumed the double-blind, international Phase IIb PEARL-SC trial in up to 600 patients comparing a weekly low or high dose of subcutaneous A-623, a monthly high dose of A-623 and placebo. Last year, Anthera suspended enrollment and dosing in...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >